AMD3100在非霍奇金淋巴瘤或多发性骨髓瘤患者中用于动员CD34+细胞的临床应用。 - Suppr

Suppr

超能文献

Clinical use of AMD3100 to mobilize CD34+ cells in patients affected by non-Hodgkin's lymphoma or multiple myeloma.

作者信息

Grignani Giovanni, Perissinotto Eliana, Cavalloni Giuliana, Carnevale Schianca Fabrizio, Aglietta Massimo

出版信息

J Clin Oncol. 2005 Jun 1;23(16):3871-2; author reply 3872-3. doi: 10.1200/JCO.2005.55.250.

DOI:10.1200/JCO.2005.55.250

PMID:15923599

Abstract

摘要

相似文献

Clinical use of AMD3100 to mobilize CD34+ cells in patients affected by non-Hodgkin's lymphoma or multiple myeloma.AMD3100在非霍奇金淋巴瘤或多发性骨髓瘤患者中用于动员CD34+细胞的临床应用。

J Clin Oncol. 2005 Jun 1;23(16):3871-2; author reply 3872-3. doi: 10.1200/JCO.2005.55.250.

Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma.在多发性骨髓瘤和非霍奇金淋巴瘤患者中给予CXCR4拮抗剂AMD3100后CD34+细胞的快速动员。

J Clin Oncol. 2004 Mar 15;22(6):1095-102. doi: 10.1200/JCO.2004.07.131.

Toward a more rational policy for autologous hematopoietic stem cell mobilization.迈向更合理的自体造血干细胞动员政策。

Biol Blood Marrow Transplant. 2012 Oct;18(10):1468-70. doi: 10.1016/j.bbmt.2012.08.001. Epub 2012 Aug 11.

Plerixafor in the treatment of progenitor cell mobilization failure: First experience in Algeria.普乐沙福治疗祖细胞动员失败：阿尔及利亚的首例经验。

Hematol Oncol Stem Cell Ther. 2015 Jun;8(2):93-4. doi: 10.1016/j.hemonc.2014.11.007. Epub 2014 Dec 27.

AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data.AMD3100联合粒细胞集落刺激因子（G-CSF）能够成功动员非霍奇金淋巴瘤、霍奇金病和多发性骨髓瘤患者的CD34+细胞，这些患者此前接受化疗和/或细胞因子治疗后动员失败：同情用药数据。

Bone Marrow Transplant. 2008 Feb;41(4):331-8. doi: 10.1038/sj.bmt.1705908. Epub 2007 Nov 12.

Plerixafor as first- and second-line strategies for autologous stem cell mobilization in patients with non-Hodgkin's lymphoma or multiple myeloma.培洛昔福作为非霍奇金淋巴瘤或多发性骨髓瘤患者自体干细胞动员的一线和二线策略。

Pharmacotherapy. 2012 Jul;32(7):596-603. doi: 10.1002/j.1875-9114.2012.01096.x.

Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma.普乐沙福在非霍奇金淋巴瘤和多发性骨髓瘤患者中的药代动力学和药效学

Biol Blood Marrow Transplant. 2009 Jan;15(1):39-46. doi: 10.1016/j.bbmt.2008.10.018.

Treatment with plerixafor in non-Hodgkin's lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patient.在非霍奇金淋巴瘤和多发性骨髓瘤患者中，当给予粒细胞集落刺激因子（G-CSF）动员方案时，使用普乐沙福增加外周血干细胞数量：对经过大量预处理患者的意义。

Biol Blood Marrow Transplant. 2009 Feb;15(2):249-56. doi: 10.1016/j.bbmt.2008.11.028.

The AMD3100 story: the path to the discovery of a stem cell mobilizer (Mozobil).AMD3100的故事：发现一种干细胞动员剂（莫扎比利）的历程。

Biochem Pharmacol. 2009 Jun 1;77(11):1655-64. doi: 10.1016/j.bcp.2008.12.014. Epub 2008 Dec 31.

Plerixafor: A chemokine receptor-4 antagonist for mobilization of hematopoietic stem cells for transplantation after high-dose chemotherapy for non-Hodgkin's lymphoma or multiple myeloma.普乐沙福：一种趋化因子受体-4 拮抗剂，用于高剂量化疗治疗非霍奇金淋巴瘤或多发性骨髓瘤后移植造血干细胞的动员。

Clin Ther. 2010 May;32(5):821-43. doi: 10.1016/j.clinthera.2010.05.007.

引用本文的文献

Role and Therapeutic Targeting of SDF-1α/CXCR4 Axis in Multiple Myeloma.基质细胞衍生因子-1α/趋化因子受体4轴在多发性骨髓瘤中的作用及治疗靶向

Cancers (Basel). 2021 Apr 9;13(8):1793. doi: 10.3390/cancers13081793.

Parameters affecting successful stem cell collections for genetic therapies in sickle cell disease.影响镰状细胞病基因治疗中干细胞成功采集的因素。

Transfus Apher Sci. 2021 Feb;60(1):103059. doi: 10.1016/j.transci.2021.103059. Epub 2021 Jan 10.

ROS-Induced CXCR4 Signaling Regulates Mantle Cell Lymphoma (MCL) Cell Survival and Drug Resistance in the Bone Marrow Microenvironment via Autophagy.活性氧诱导的CXCR4信号通过自噬调节骨髓微环境中的套细胞淋巴瘤（MCL）细胞存活和耐药性。

Clin Cancer Res. 2016 Jan 1;22(1):187-99. doi: 10.1158/1078-0432.CCR-15-0987. Epub 2015 Sep 8.

Plerixafor plus pegfilgrastim is a safe, effective mobilization regimen for poor or adequate mobilizers of hematopoietic stem and progenitor cells: a phase I clinical trial.普乐沙福联合培非格司亭对于造血干细胞和祖细胞动员不佳或动员效果一般的患者而言，是一种安全有效的动员方案：一项I期临床试验。

Bone Marrow Transplant. 2014 Aug;49(8):1056-62. doi: 10.1038/bmt.2014.112. Epub 2014 Jun 2.

Increased mobilization and yield of stem cells using plerixafor in combination with granulocyte-colony stimulating factor for the treatment of non-Hodgkin's lymphoma and multiple myeloma.使用普乐沙福联合粒细胞集落刺激因子提高干细胞的动员和产量，用于治疗非霍奇金淋巴瘤和多发性骨髓瘤。

Stem Cells Cloning. 2011 Feb 27;4:11-22. doi: 10.2147/SCCAA.S6713. eCollection 2011.

The effective use of plerixafor as a real-time rescue strategy for patients poorly mobilizing autologous CD34(+) cells.将普乐沙福有效用作动员自体CD34(+)细胞不佳患者的即时救援策略。

J Clin Apher. 2012;27(2):81-7. doi: 10.1002/jca.21206. Epub 2012 Feb 2.

G-CSF supplementation with chemotherapy can promote revascularization and subsequent tumor regrowth: prevention by a CXCR4 antagonist.化疗联合 G-CSF 治疗可促进血管再生及随后的肿瘤复发：CXCR4 拮抗剂的预防作用。

Blood. 2011 Sep 22;118(12):3426-35. doi: 10.1182/blood-2010-11-320812. Epub 2011 Jun 17.

The CXCR4 Antagonist AMD3100 Has Dual Effects on Survival and Proliferation of Myeloma Cells In Vitro.AMD3100 是一种 CXCR4 拮抗剂，对骨髓瘤细胞的体外存活和增殖有双重作用。

Cancer Res Treat. 2010 Dec;42(4):225-34. doi: 10.4143/crt.2010.42.4.225. Epub 2010 Dec 31.

Plerixafor: in patients with non-Hodgkin's lymphoma or multiple myeloma.普乐沙福：用于非霍奇金淋巴瘤或多发性骨髓瘤患者。

Drugs. 2009;69(3):319-26. doi: 10.2165/00003495-200969030-00007.

CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy.CXCR4抑制剂AMD3100破坏多发性骨髓瘤细胞与骨髓微环境之间的相互作用，并增强它们对治疗的敏感性。

Blood. 2009 Apr 30;113(18):4341-51. doi: 10.1182/blood-2008-10-186668. Epub 2009 Jan 12.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验